Newsletter Signup | Join Community
Local ablative treatment combined with immunotherapy improves long term survival in oligometastatic NSCLC.
Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.
Research suggests that tumor mutational burden assessment can help predict response to immunotherapy in NSCLC.
BLU-667 targets RET fusion proteins and can be used to treat 1-2% of NSLC patients with the RET mutation.
Tecentriq® Improves NSCLC survival when combined with Avastin & chemotherapy Regardless of PD-L1 Status.
What is the evidence and current recommendations for lung cancer screening?
FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…